No Data
No Data
IRONWOOD PHARMACEUTICALS Earnings Preview: Recent $IRWD Insider Trading, Hedge Fund Activity, and More
Insider Sale: Chief Executive Officer of $IRWD Sells 139,064 Shares
It's Time for Investors to Rotate, With Opportunities Down the Market Cap – Piper Sandler
Express News | S&P Dow Jones Indices: Following the Spin-off, Lennar Will Remain in the S&P 500
Express News | Millrose Properties To Replace Ironwood Pharmaceuticals In S&P SmallCap 600, Effective Prior To Opening Of Trading On February 10
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating, Maintains Target Price $7